---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-22-001006"
form_type: "8-K"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2022-03-09T23:59:59+00:00"
generated_at: "2026-06-27T00:22:59.255603+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Chemomab reports FY2021 net loss of $12.5M; revises CM-101 clinical program to extend cash runway through end 2023

## Summary
- Net loss $12.5M ($0.06 per share) in FY2021 vs $6.0M in FY2020; cash $61.2M at Dec 31, 2021.
- Expanding Phase 2 PSC trial with dose-finding cohorts and open-label extension; interim analysis expected H2 2022.
- Focusing SSc trial on earlier proof of concept; trial initiation anticipated H2 2022.
- Winding down liver fibrosis subcutaneous formulation study; data readout targeted near end of 2022.
- Cash runway extended ~6 months to end of 2023; company expects 3-4 data readouts over next 24 months.

## SEC filing metadata
- accession: 0001178913-22-001006
- form_type: 8-K
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2022-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891322001006/0001178913-22-001006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891322001006/zk2227450.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-22-001006
- JSON: https://secwatch.observer/filing/0001178913-22-001006.json
- Plain text: https://secwatch.observer/filing/0001178913-22-001006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.